Zobrazeno 1 - 10
of 809
pro vyhledávání: '"D. PINKEL"'
Kniha
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
D Pinkel
Publikováno v:
Leukemia. 23:2189-2196
‘Allogeneic marrow transplantation in children with acute leukemia: a practice whose time has gone’: twenty years later
Publikováno v:
Cancer Investigation. 15:121-126
High-dose, continuous infusion of intravenous mercaptopurine (HD 6MP) followed by intermediate-dose continuous cytarabine (ID Ara-C) has been shown to produce remissions in children with relapsed acute myeloid leukemia (AML). The purpose of this pilo
Publikováno v:
Cancer. 77:563-569
BACKGROUND: Ethnic differences in the survival of children treated for acute lymphoid leukemia (ALL) have been described in several locations. Children of African, Polynesian, Native American, and Mexican ancestry had a less favorable outcome than ch
Publikováno v:
Molecular Reproduction and Development. 40:259-266
A multicolor procedure employing fluorescence in situ hybridization is described for detecting chromosomal domains and germinal aneuploidy in late-step spermatids in mice using DNA probes specific for repetitive sequences near the centromeres of chro
Autor:
J J Shuster, DJ Pullen, Michael E. Harris, V J Land, Yaddanapudi Ravindranath, Robert A. Krance, D. Pinkel, W M Crist
Publikováno v:
Journal of Clinical Oncology. 12:1939-1945
PURPOSE To compare efficacy and toxicity of two schedules of intermediate-dose methotrexate (IDM) and cytarabine (Ara-C) in remission consolidation of childhood acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS In 1986, the Pediatric Oncology
Autor:
D. Pinkel, Shiao Y. Woo
Publikováno v:
Blood. 84:355-366
The prevention of meningeal leukemia has long been a keystone in its cure. The need was recognized when it became apparent in the 1950s and 1960s that meningeal relapse heralded hematologic relapse and a fatal course and that its incidence increased
Publikováno v:
Journal of Clinical Oncology. 12:587-595
PURPOSE This phase I/II study was designed to explore the feasibility, toxicity, and potential efficacy of administering high-dose continuous intravenous mercaptopurine (6MP) followed by intermediate-dose continuous intravenous cytarabine (Ara-C) to